772 related articles for article (PubMed ID: 21860026)
21. Multiple myeloma cells' capacity to decompose H
Sebastian S; Zhu YX; Braggio E; Shi CX; Panchabhai SC; Van Wier SA; Ahmann GJ; Chesi M; Bergsagel PL; Stewart AK; Fonseca R
Blood; 2017 Feb; 129(8):991-1007. PubMed ID: 28028022
[TBL] [Abstract][Full Text] [Related]
22. ARID2 is a pomalidomide-dependent CRL4
Yamamoto J; Suwa T; Murase Y; Tateno S; Mizutome H; Asatsuma-Okumura T; Shimizu N; Kishi T; Momose S; Kizaki M; Ito T; Yamaguchi Y; Handa H
Nat Chem Biol; 2020 Nov; 16(11):1208-1217. PubMed ID: 32958952
[TBL] [Abstract][Full Text] [Related]
23. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
Patil A; Manzano M; Gottwein E
Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751
[TBL] [Abstract][Full Text] [Related]
24. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
Jonasova A; Bokorova R; Polak J; Vostry M; Kostecka A; Hajkova H; Neuwirtova R; Siskova M; Sponerova D; Cermak J; Mikulenkova D; Cervinek L; Brezinova J; Michalova K; Fuchs O
Eur J Haematol; 2015 Jul; 95(1):27-34. PubMed ID: 25284710
[TBL] [Abstract][Full Text] [Related]
25. Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs.
Gemechu Y; Millrine D; Hashimoto S; Prakash J; Sanchenkova K; Metwally H; Gyanu P; Kang S; Kishimoto T
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):11802-11807. PubMed ID: 30373817
[TBL] [Abstract][Full Text] [Related]
26. [Immunomodulatory drugs (IMiDs)].
Oshima K; Ichinohe T
Nihon Rinsho; 2014 Jun; 72(6):1130-5. PubMed ID: 25016816
[TBL] [Abstract][Full Text] [Related]
27. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
Ocio EM; Fernández-Lázaro D; San-Segundo L; López-Corral L; Corchete LA; Gutiérrez NC; Garayoa M; Paíno T; García-Gómez A; Delgado M; Montero JC; Díaz-Rodríguez E; Mateos MV; Pandiella A; Couto S; Wang M; Bjorklund CC; San-Miguel JF
Leukemia; 2015 Mar; 29(3):705-14. PubMed ID: 25102946
[TBL] [Abstract][Full Text] [Related]
28. Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships.
Burslem GM; Ottis P; Jaime-Figueroa S; Morgan A; Cromm PM; Toure M; Crews CM
ChemMedChem; 2018 Aug; 13(15):1508-1512. PubMed ID: 29870139
[TBL] [Abstract][Full Text] [Related]
29. Lenalidomide affect expression level of cereblon protein in multiple myeloma cell line RPMI8226.
Yang DY; Ren JH; Guo XN; Guo XL; Cai XY; Guo XF; Zhang JN
Genet Mol Res; 2015 Oct; 14(4):13588-94. PubMed ID: 26535672
[TBL] [Abstract][Full Text] [Related]
30. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.
Broyl A; Kuiper R; van Duin M; van der Holt B; el Jarari L; Bertsch U; Zweegman S; Buijs A; Hose D; Lokhorst HM; Goldschmidt H; Sonneveld P; ;
Blood; 2013 Jan; 121(4):624-7. PubMed ID: 23233657
[TBL] [Abstract][Full Text] [Related]
31. Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.
Xu Q; Hou YX; Langlais P; Erickson P; Zhu J; Shi CX; Luo M; Zhu Y; Xu Y; Mandarino LJ; Stewart K; Chang XB
BMC Cancer; 2016 May; 16():297. PubMed ID: 27142104
[TBL] [Abstract][Full Text] [Related]
32. Homo-PROTACs for the Chemical Knockdown of Cereblon.
Steinebach C; Lindner S; Udeshi ND; Mani DC; Kehm H; Köpff S; Carr SA; Gütschow M; Krönke J
ACS Chem Biol; 2018 Sep; 13(9):2771-2782. PubMed ID: 30118587
[TBL] [Abstract][Full Text] [Related]
33. [Development of novel cereblon modulators and their target molecules].
Ito T
Rinsho Ketsueki; 2022; 63(6):573-579. PubMed ID: 35831190
[TBL] [Abstract][Full Text] [Related]
34. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
Das DS; Ray A; Song Y; Richardson P; Trikha M; Chauhan D; Anderson KC
Br J Haematol; 2015 Dec; 171(5):798-812. PubMed ID: 26456076
[TBL] [Abstract][Full Text] [Related]
35. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.
Bjorklund CC; Kang J; Amatangelo M; Polonskaia A; Katz M; Chiu H; Couto S; Wang M; Ren Y; Ortiz M; Towfic F; Flynt JE; Pierceall W; Thakurta A
Leukemia; 2020 Apr; 34(4):1197-1201. PubMed ID: 31719682
[No Abstract] [Full Text] [Related]
36. The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance.
Zou J; Jones RJ; Wang H; Kuiatse I; Shirazi F; Manasanch EE; Lee HC; Sullivan R; Fung L; Richard N; Erdman P; Torres E; Hecht D; Lam I; McElwee B; Chourasia AH; Chan KWH; Mercurio F; Stirling DI; Orlowski RZ
J Mol Med (Berl); 2020 Aug; 98(8):1161-1173. PubMed ID: 32632752
[TBL] [Abstract][Full Text] [Related]
37. The molecular mechanism of thalidomide analogs in hematologic malignancies.
Lindner S; Krönke J
J Mol Med (Berl); 2016 Dec; 94(12):1327-1334. PubMed ID: 27492707
[TBL] [Abstract][Full Text] [Related]
38. Modulation of cereblon levels by anti-myeloma agents.
Díaz-Rodríguez E; Pandiella A
Leuk Lymphoma; 2016; 57(1):167-76. PubMed ID: 25860244
[TBL] [Abstract][Full Text] [Related]
39. [Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
Roziaková L; Mistrík M; Bátorová A
Klin Onkol; 2014; 27(5):318-25. PubMed ID: 25312708
[TBL] [Abstract][Full Text] [Related]
40. Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment in multiple myeloma patients?
Bedewy AM; El-Maghraby SM
Eur J Haematol; 2014 Jan; 92(1):13-8. PubMed ID: 24118365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]